● Recruiting

Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

Condition: Glioma · Sponsor: Plus Therapeutics

PhasePhase 1

Planned participants40

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) for recurrence glioma in patients who received a prior treatment of 186RNL.

This description comes directly from the study's public registry record.

Talk to the study team

Rachael Hershey · 1(210) 791-8723 · patients@respect-trials.com

Andrew Brenner, PhD · 1(210) 791-8723 · patients@respect-trials.com

Always discuss trial participation with your own doctor first.

Locations (1)

The Cancer Therapy and Research Center at UTHSCSA

San Antonio, Texas, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05460507